The body responds to synthetic surfaces on implanted prosthetic devices with an inflammatory foreign body response (FBR), which results in the gradual deposition of a fibrous collagenous capsule. Capsular contracture (CC), the progressive growth and contraction of this peri-prosthetic capsule, is the most common complication of aesthetic and reconstructive breast surgery, affecting up to 47.5% of patients (1). CC causes breast pain, hardening, and deformity and is the most common indication for revision surgery. CC is thought to be due to an excessive FBR, however the etiology and pathophysiology of this process is poorly understood, and CC can occur in the absence of any putative risk factors. As such, there are no clinically approved therapies for prevention or treatment of CC. Rather, the complication is mitigated with re-operation and capsule excision, which often necessitates implant removal and replacement. Herein we altered the surface chemistry of silicone implants with Sigilon's proprietary anti-inflammatory molecules, E9 and RZA15. These compounds are biocompatible small organic molecules which are covalently grafted to the surface of the implant. They are designed to reduce immune cell adhesion to the implant, leading to a truncated FBR and reduced fibrosis.
PURPOSE:
The body responds to synthetic surfaces on implanted prosthetic devices with an inflammatory foreign body response (FBR), which results in the gradual deposition of a fibrous collagenous capsule. Capsular contracture (CC), the progressive growth and contraction of this peri-prosthetic capsule, is the most common complication of aesthetic and reconstructive breast surgery, affecting up to 47.5% of patients (1). CC causes breast pain, hardening, and deformity and is the most common indication for revision surgery. CC is thought to be due to an excessive FBR, however the etiology and pathophysiology of this process is poorly understood, and CC can occur in the absence of any putative risk factors. As such, there are no clinically approved therapies for prevention or treatment of CC. Rather, the complication is mitigated with re-operation and capsule excision, which often necessitates implant removal and replacement. Herein we altered the surface chemistry of silicone implants with Sigilon's proprietary anti-inflammatory molecules, E9 and RZA15. These compounds are biocompatible small organic molecules which are covalently grafted to the surface of the implant. They are designed to reduce immune cell adhesion to the implant, leading to a truncated FBR and reduced fibrosis.
METHODS:
Round silicone implants were created from polydimethylsiloxane (PDMS). RZA15 or E9, two novel, biocompatible, non-toxic, anti-inflammatory proprietary molecules were covalently bonded to the implants. Uncoated, RZA15-and E9-coated implants were implanted subcutaneously into the dorsa of wildtype C57Bl/6 mice. After 21 and 90 days, peri-prosthetic tissue was removed for histologic analysis, and stained with Hematoxylin & Eosin and Masson's Trichrome. The capsule was identified at five equidistant regions throughout the implant and outlined in ImageJ software. Capsule area was calculated, and divided by capsule length to determine the average capsule thickness per implant.
RESULTS:
We compared mean capsular thickness at two time points across the three groups: E9-coated, RZA15-coated, and uncoated implants. After 21 days, there was a statistically significant reduction in capsule thickness of RZA15-(71.12 microns; p = 0.0194) and E9-coated implants (76.84 microns; p = 0.0463) compared to uncoated implants (103.80 microns). Similarly, after 90 days, there was a statistically significant reduction in capsule thickness E9-coated implants (40.51 microns; p = 0.023) compared to uncoated implants (59.16 microns).
CONCLUSION:
Coating the surface of silicone implants with RZA15 and E9 significantly reduced both acute (3 weeks) and chronic (3 months) capsule formation in a mouse model for implant-based breast augmentation and reconstruction. As capsule formation obligatorily precedes capsular contracture, these results suggest contracture itself may be significantly attenuated. Furthermore, as peri-prosthetic capsule formation is a complication without anatomical boundaries, the chemistry of this novel compound may have additional applications beyond breast implants, to a myriad of other implantable medical devices. We recently developed a serum-free, ex vivo cell expansion system called Mononuclear Cell Quality and Quantity Control Culture System (MNC-QQc), using peripheral blood mononuclear cells (MNCs), to increase the number and the vasculogenic property of endothelial progenitor cells (EPCs) for enhanced vasculogenesis and tissue regeneration from a small amount of peripheral blood. Recently, the effect of microgravity (MG) was reported to enhance the potential of various stem cells. Therefore, we investigated whether combination of MG will enhance the function of our culture system. The purpose of this study was to evaluate the efficacy of MG on MNC-QQc to increase the number and function of peripheral blood EPCs.
METHODS:
MG culture condition was established using disposable cell container (DCC) on 3D-clinostat (Mitsubishi Heavy Industries, Ltd., Tokyo, Japan). MNCs were isolated from peripheral blood in healthy volunteers (n = 8). Cells were cultured in MNC-QQc under four different conditions: (1) normal MNC-QQc (Normal Control; NC), (2) earth gravity during 7 days in DCC (Earth Gravity; EG), (3) MG during 7 days in DCC (MG), and (4) MG for 3 days followed by EG for 4 days in DCC (Microgravity and Earth Gravity; ME). After 7 days of MNC-QQc, total cell number and percentage of CD34-positive cells were measured by FACS analysis, as an indicator of EPCs. The vascular regeneration ability of MNC-QQc cells was evaluated by identifying definitive EPC colony-forming units (dEPC-CFU) and primitive EPC CFU (pEPC-CFU) in colony forming assays (EPC-CFA).
RESULTS:
While none of the culture conditions changed the total number of cells, the MG and ME groups showed significantly higher number of CD34-positive cells than the NC group [MG vs NC (4.37 ± 2.65 vs 1.32 ± 0.31, p <0.05) and ME vs NC (4.74 ± 2.96 vs 1.32 ± 0.31, p <0.05)]; there was no significant difference between the EG and NC groups (3.76 ± 2.78 vs 1.32 ± 0.31). The total EPC-CFU number did not differ among the four groups (NC: 944.4 ± 646.9, EG: 1043.0 ± 710.2, MG: 1084.7 ± 645.6, ME:1487.4 ± 528.3). However, the dEPC-CFU number, which demonstrates the differentiation potential of EPCs, was significantly increased in ME compared to that in NC (1329.1 ± 573.4 vs 688.3 ± 513.0, p <0.05) and other groups.
CONCLUSION:
MNCs that underwent QQ culture under MG give rise to higher CD34-positive fraction compared to those in EG culture. In addition, higher EPC vasculogenic function was seen in ME. This group especially showed increased differentiation potential of EPCs, as revealed by increase in dEPC-CFU. The results indicated that MNCQQc in combination with MG-EG conditions may be a more effective EPC expansion culture method and is a potentially valuable tool for therapeutic vasculogenesis and tissue regeneration. University of Utah, Salt Lake City, UT PURPOSE: Nerve conduits are a promising alternative to autografts and can act as guidance cues for the regenerating axons and allow for tension free bridging, without the need to harvest donor nerve. It has also been shown that locally delivering nerve growth factor (NGF) can enhance peripheral nerve recovery. There are major benefits in providing a guidance conduit that can independently deliver localized drugs to the injury site. A bulk diffusion delivery device will provide flexibility in easily altering the drug of choice and precision in using traditional fluid mechanics to control delivery rather than complex polymer degradation. This paper describes the in vitro and in vivo outcomes of a novel drug delivery apparatus integrated with a PLGA (poly lactic-co-glycolic acid) based nerve guide conduit for controlled local delivery of NGF.
METHODS:
The device consists of two concentric tubes and a reservoir in between the tubes that stores NGF. All device components were manufactured using 75/25 poly-lactic-glycolic-acid (Evonik). A 120μm diffusion hole was drilled into the inner conduit by pulsing a laser cutter. In vitro release tests were performed over a 4-week period. Concentration of NGF released from conduits was determined with an ELISA (R&D systems). The released NGF was collected every 3-4 days, and the bioactivity of the released NGF was determined using a chick dorsal root ganglion (DRG) based bioassay. In vivo testing of the NGF-delivering conduit (n=8) was performed in a rat sciatic nerve gap model and compared with negative control (empty conduits, n=8). The animals
